Abstract
Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer: Erratum
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have